Welcome to our dedicated page for Cara Therapeutic news (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutic stock.
Cara Therapeutics, Inc. (CARA) is a clinical-stage biopharmaceutical company pioneering novel therapies for pain, inflammation, and pruritus. This page serves as the definitive source for verified corporate announcements, clinical trial developments, and strategic business updates.
Investors and industry observers will find timely updates on CARA's drug development pipeline, including progress on its lead therapeutic candidates and proprietary screening technology. The curated news collection features earnings reports, regulatory filings, partnership announcements, and scientific presentations.
Key content undergoes rigorous verification to ensure accuracy, with updates spanning clinical trial milestones, research collaborations, and financial performance. Regular updates provide insights into CARA's position within the competitive biotech sector and its progress toward addressing unmet medical needs.
Bookmark this page for streamlined access to CARA's latest developments, including FDA communications, peer-reviewed study publications, and executive leadership insights. Check back frequently for comprehensive coverage of this innovative biopharmaceutical company.
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kapruvia® (difelikefalin) for treating chronic kidney disease-associated pruritus in hemodialysis patients. This therapy would be the first of its kind in
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Kapruvia® (difelikefalin) for treating chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients in Europe. This marks a significant advance as Kapruvia would be the first therapy available for this condition in Europe. An official decision from the European Commission is anticipated in Q2 2022. The drug is already approved in the U.S. under the name KORSUVA™.
Cara Therapeutics, Inc. (Nasdaq: CARA) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and provide company updates. The call will be accessible via phone or a live audio webcast on their website. Cara is focused on pruritus treatments and has FDA-approved KORSUVA™ (difelikefalin) for moderate-to-severe pruritus associated with chronic kidney disease. The company is also developing an oral version and plans to initiate Phase 3 programs in early 2022.
Cara Therapeutics (Nasdaq: CARA) has announced a virtual R&D event set for March 11, 2022, from 1:00 to 2:00 p.m. ET, focusing on the oral difelikefalin Phase 3 programs aimed at treating pruritus in patients suffering from atopic dermatitis and chronic kidney disease.
The event will feature key presenters, including CEO Christopher Posner and prominent medical professionals. A live audio webcast will be available on Cara's website, with a replay accessible afterward.
Cara Therapeutics announced the success of its licensor Maruishi Pharmaceutical in a Phase 3 study of difelikefalin injection for treating pruritus in hemodialysis patients. The trial achieved both primary and secondary endpoints, significantly reducing itch scores compared to placebo. Difelikefalin has shown good tolerance among patients. Following FDA approval in August 2021 for moderate-to-severe pruritus associated with chronic kidney disease, the U.S. launch is expected in Q2 2022. The European Medicines Agency is also reviewing its marketing application.
Cara Therapeutics (Nasdaq: CARA) announced that CEO Christopher Posner will present an overview at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. ET. The presentation will be available for live streaming and can be accessed from the company's website. Cara Therapeutics focuses on innovative treatments for pruritus, including KORSUVA™ (difelikefalin), the first FDA-approved therapy for chronic kidney disease-related pruritus. The company is also advancing an oral formulation of KORSUVA and has ongoing Phase 2 trials for additional conditions.
Cara Therapeutics (CARA) announced that the U.S. Centers for Medicare & Medicaid Services granted Transitional Drug Add-On Payment Adjustment (TDAPA) for its product KORSUVA (difelikefalin) injection, effective April 4, 2022, for two years. This approval facilitates reimbursement for new therapies in the end-stage renal disease category, aiding the upcoming commercial launch planned for early Q2 2022. KORSUVA, FDA-approved in August 2021, targets moderate-to-severe pruritus in chronic kidney disease patients on hemodialysis. This move supports access to innovative treatments for those in need.
Cara Therapeutics, Inc. (Nasdaq: CARA) announced participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. The chat will feature Christopher Posner, CEO, Thomas Reilly, CFO, and Joana Goncalves, M.D., CMO. A webcast of the event will be available on the company’s website and archived for approximately 30 days.
Cara, focused on alleviating pruritus through kappa opioid receptors, received FDA approval for KORSUVA Injection on August 23, 2021, targeting chronic kidney disease-related pruritus.
Cara Therapeutics, Inc. (Nasdaq: CARA) announced participation by CEO Christopher Posner in two investor conferences this November. The Stifel 2021 Virtual Healthcare Conference will host a fireside chat on November 15 at 1:20 p.m. ET, and the Jefferies London Healthcare Conference will feature a chat on November 18 at 3:00 a.m. ET. Webcasts will be accessible via the company's website and archived for 30 days. Cara Therapeutics focuses on developing treatments to alleviate pruritus through its innovative drug, KORSUVA, which recently received FDA approval for treating CKD-aP.
Cara Therapeutics announced the FDA approval of KORSUVA™ injection for treating chronic kidney disease-associated pruritus in hemodialysis patients, the first of its kind. CEO Christopher Posner will take over on November 9, 2021. The company reported a revenue increase to $20.3 million in Q3 2021, compared to $9.3 million in Q3 2020, alongside a net loss reduction to $1.0 million. R&D expenses decreased to $15.5 million. Cara expects its cash will be sufficient to fund operations through 2023. A conference call is set for 4:30 p.m. ET.
